CN103735603A - Compound lipid-decreasing soft capsule and preparation method thereof - Google Patents
Compound lipid-decreasing soft capsule and preparation method thereof Download PDFInfo
- Publication number
- CN103735603A CN103735603A CN201410047695.9A CN201410047695A CN103735603A CN 103735603 A CN103735603 A CN 103735603A CN 201410047695 A CN201410047695 A CN 201410047695A CN 103735603 A CN103735603 A CN 103735603A
- Authority
- CN
- China
- Prior art keywords
- soft capsule
- radix notoginseng
- preparation
- parts
- decreasing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a compound lipid-decreasing soft capsule and a preparation method thereof. The compound lipid-decreasing soft capsule is characterized by mainly comprising the following main parts: folium ginkgo, pseudo-ginseng, gynostemma pentaphylla, red yeast rice and seabuckthorn seed oil. According to the invention, the compatibility between traditional Chinese medicines and raw materials is mainly used, so as to develop a Chinese medicinal formulae for effectively preventing and decreasing lipid, meanwhile, for overcoming defects of inconvenience in decoction, carrying and taking, incomplete decocted components, bad mouthfeel and the like in the conventional dosage form decoction at present, the decoction is prepared into modern soft capsule form achieving accurate quantification through a modern drug mean, the bioavailability is improved, the compound lipid-decreasing soft capsule is enabled to be more remarkable in effect and convenient to take, objectionable odors and bitter taste in the traditional Chinese medicines can be covered up, so as to be accepted by people easily, and the lipid-decreasing effect can be better achieved.
Description
Technical field
The present invention relates to medicines and health protection technical field, be specifically related to a kind of compound antihyperglycemic soft capsule and preparation method thereof.
Background technology
Hyperlipidemia belongs to the traditional Chinese medical science " expectorant is turbid ", " blood stasis " category.The traditional Chinese medical science thinks, phlegm retention is due to visceral dysfunctions such as lung, spleen, kidneys, make the transporting of body fluid, defeated cloth and excretion that obstacle occur, and in the stagnant body of the stasis of blood, cold coagulation intimately forms in addition.Therefore, hyperlipidemia pathological change is main and the dirty functional disorder of liver,spleen,kidney three is in close relations, the clinical deficiency in origin and excess in superficiality determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs mainly with gas, blood, expectorant, silt.
Raising along with China's living standards of the people, there is obvious variation in dietary structure, the intake of satisfied fatty acid and cholesterol increases, and the intake of carbohydrate reduces just gradually, by being originally conducive to healthy dietary structure, changed the dietary structure that is unfavorable for the healthy high fat that is enough to cause dyslipidemia, hypercholesterolemia, low-carb into.Hyperlipidemia sickness rate increases year by year, and age of onset has the trend of rejuvenation gradually, because hyperlipidemia causes cardiovascular and cerebrovascular disease that atherosclerosis causes, has become serious threat human life's formidable enemy.From normal tremulous pulse to asymptomatic atherosclerosis, stricture of artery, need more than ten years to the time of more than two decades, be a very very long process.And from asymptomatic atherosclerosis to causing cardiovascular and cerebrovascular disease (as heart disease or apoplexy), but as long as short a few minutes.Therefore prevent cardiovascular and cerebrovascular disease from setting about in early days, to prevent more to overweight treatment.Except active treatment hyperlipidemia, strengthen daily health caring, active development health food easily and effectively, to preventing and treating arteriosclerosis, the sickness rate that reduces cardiovascular and cerebrovascular disease is significant.
Understanding based on to the untoward reaction of blood fat reducing Western medicine and traditional Chinese medical science blood fat reducing advantage, people more and more pay attention to using the anti-curing hyperlipemia of thinking model of traditional Chinese medical science organic conception.Chinese medicine blood fat reducing is by reducing the absorption of exogenous lipid, reduces the synthetic of endogenous lipid, promotes transhipment and the excretion of lipid, regulating lipid metabolism.Therefore, utilize Chinese Traditional Medicine resource, utilize modern biology and preparation technique, it is the ideal that vast researcher is benefited sufferer that research and development are applicable to auxiliary medicine and the health food that reduces hyperlipidemia of having of long-term taking.
Summary of the invention
Technical problem to be solved by this invention is, there is decoction in the conventional dosage forms decoction for the current traditional Chinese medical science, carry, take inconvenience, and composition is fried not exclusively, the defects such as mouthfeel is poor, the present invention mainly uses Chinese medicine to follow the compatibility relationship of stock yard, exploitation is the Chinese medicinal formulae of blood fat reducing effectively, and by modern medicinal agents means made can accurate quantitative analysis modern soft capsule dosage form, improve bioavailability, make the drug effect of preparation of the present invention more remarkable, take more convenient, cover bad smell and the bitterness of Chinese medicine, make people be easy to accept, more can reach preferably fat-reducing effect.
The object of this invention is to provide a kind of compound antihyperglycemic soft capsule, it has the effect of prevention and treatment hyperlipidemia.
Another object of the present invention is to provide the preparation method of above-mentioned compound antihyperglycemic soft capsule.
It is achieved by the following scheme:
A compound antihyperglycemic soft capsule, is characterized in that, in described compound antihyperglycemic soft capsule, main component is: Folium Ginkgo, Radix Notoginseng, Herb Gynostemmae Pentaphylli, Monas cuspurpureus Went, Fructrs Hippophae seed oil.
Further, the weight proportion of described each raw material components Folium Ginkgo, Radix Notoginseng, Herb Gynostemmae Pentaphylli, Monas cuspurpureus Went, Fructrs Hippophae seed oil is: 50～100 parts of Folium Ginkgos, 20～30 parts of Radix Notoginseng, 20～30 parts of Herb Gynostemmae Pentaphylli, 5～10 parts, Monas cuspurpureus Went, 45～75 parts of Fructrs Hippophae seed oil.
A preparation method for compound antihyperglycemic soft capsule, is characterized in that, its preparation method comprises the steps:
1) Folium Ginkgo is cleaned, is dried, and pulverizes and sieves;
2) Radix Notoginseng pulverizes and sieves;
3) get ginkgo leaf powder and the Radix Notoginseng powder of weight portion meter, the ethanol that the concentration that adds 10 times of amounts of above-mentioned Chinese medicine powder is 70% is heated to 60 ℃～70 ℃ in water-bath, lixiviate 1.5h, every 10min stirs once, filters the ethanol that the concentration that adds 8 times of amounts in residue is 70% with husky cloth, 60 ℃～70 ℃ are continued lixiviate 1.5h, every 10min stirs once, filtered through gauze, and medicinal residues discard, merge extractive liquid,, standby;
4) get above-mentioned filtrate, put in vacuum decompressioning and concentrating tank, reclaim ethanol to without alcohol taste and to be concentrated into relative density be that 1.20～1.25(50 ℃ of heat is surveyed), obtain thick paste;
5) get above-mentioned thick paste, with reduced vacuum drying baker, be heated to 60 ℃ and be dried, obtain dry extract, and pulverize with universal mill, sieve, obtain dry extract;
6) Herb Gynostemmae Pentaphylli of getting weight portion meter adds 8～12 times of water, decocts 1.5～2 hours, and husky cloth filters to obtain extracting solution; Residue adds 5～8 times of water gagings again and decocts 1～1.5 hour, filters to obtain extracting solution for the second time.Concentrated after merge extractive liquid,, add ethanol to reaching 70%～90% containing alcohol amount, filter, filtrate is concentrated, be drying to obtain Herb Gynostemmae Pentaphylli extract;
7) get up-to-standard formula ratio Monas cuspurpureus Went and cross 80 mesh sieves, obtain Monas cuspurpureus Went fine powder;
8) by the gelatin of certain mass umber, glycerol, adding of purified water glue tank, stir and heat up, after gelatin melts completely, continue to be warming up to 75 ℃～80 ℃, insulated and stirred, being evacuated to viscosity is 2.5-3.5 ten thousand mpas, obtains glue; Described glue is crossed to 60～80 mesh sieves, move in storage glue tank, 55 ℃～65 ℃ insulations, standing 4-6 hour is standby;
9) by above-mentioned gained Folium Ginkgo, Radix Notoginseng, Herb Gynostemmae Pentaphylli extract and Monas cuspurpureus Went fine powder mix homogeneously and be dissolved in and make fat-reducing soft capsule content in Fructrs Hippophae seed oil;
10) use encapsulating machine, the capsule 's content of the glue of preparing by step 8) and step 9) preparation is prepared into the soft capsule that specification is 0.6g/ grain, dry, obtains.
Further, in described step 1), Folium Ginkgo was pulverized 60～80 mesh sieves; Described step 2) in, Radix Notoginseng was pulverized 60～80 mesh sieves; Vacuum-concentrcted technological parameter: vacuum 0.08Mpa in described step 4), temperature 60 C; Vacuum drying process parameter in described step 5): baking temperature is 60 ℃, vacuum is 0.08Mpa, dry gained dry extract is crossed 60～80 mesh sieves.
Further, in described step 8), glue raw material weight proportioning is 20～25 parts, gelatin, 8～10 parts of glycerol, 20～25 parts of purified water.
The present invention develops meticulously according to Chinese medicine folk tradition formula.According to theory of Chinese medical science, too high serum cholesterol, triglyceride in blood of human body, and be deposited in the lipid in blood vessel wall, and all claim " stasis of blood ", " stagnant ", removed, need blood circulation promoting and blood stasis dispelling.We study and think, simple the effect ofactivating blood circulation to dissipate blood stasis is unsatisfactory, need be aided with benefiting QI and nourishing blood.The capable blood of gas, the stagnation of QI is stasis, and the prosperous hemapodium of gas, removes stasis of blood effect more remarkable.
Folium Ginkgo mildly bitter flavor in we, property is flat.The effect of there is the beneficial heart, promoting blood circulation and stopping pain, astringing the lung and relievining asthma, the Multiple components useful to health such as its contained natural activity flavone and amarolide, there is the effect of dissolving cholesterol, blood vessel dilating, to improving disordered brain function, arteriosclerosis, hypertension, dizzy, tinnitus, headache, senile dementia, hypomnesis etc., have positive effect.Controlling of generally acknowledging at present, the optimal ingredient of anti-cardiovascular and cerebrovascular disease.
Radix Notoginseng is warm in nature, and acrid in the mouth has scattered silt hemostasis, and the effect of subduing swelling and relieving pain can be used for treating epistaxis, has blood in stool, the disease such as metrorrhagia, spitting of blood, haematemesis, traumatic hemorrhage, breast ventral spine pain.And the flavone compound in Radix Notoginseng has effect, sitosterol and the blood fat reducing of daucosterol energy that improves blood supply of cardiac muscle, increases blood vessel elasticity, coronary artery dilator.Normal food Radix Notoginseng, has preventive and therapeutic action to coronary heart diseases and angina pectoris.
Herb Gynostemmae Pentaphylli is cool in nature, bitter in the mouth, micro-sweet, has the spleen invigorating of nourishing heart, QI invigorating and blood regulating, an effect of the blood stasis dispelling of eliminating the phlegm.Can reduce blood fat, control thrombosis, regulates blood glucose, hypnotic, and slow down aging, regulates human physiological functions to improve immunity.
Monas cuspurpureus Went is warm in nature, sweet in the mouth, nontoxic, has the effect of strengthening the spleen to promote digestion, blood circulation promoting and blood stasis dispelling.Effective ingredient lovastatin in Monas cuspurpureus Went can comprehensive adjustment blood fat, realize " three fall one liter ", reduce cholesterol, triglyceride, low density lipoprotein, LDL, high density lipoprotein increasing, simultaneously can be effectively to free radical resisting, from source, suppress the formation of atherosclerotic plaque, established speckle can effectively be fixed and be melted, the generation of prevention heart infarction, cerebral infarction and sudden death.
Fructrs Hippophae seed oil is the elite of Fructus Hippophae, and clinical medicine shows, Fructus Hippophae total flavones can reduce hyperlipidemia, vessel softening, and reduces low density lipoprotein, LDL, removes blood vessel wall deposit, accelerates the metabolism of triglyceride in blood, prevents and treats atherosclerotic formation.In Fructrs Hippophae seed oil, contain abundant unsaturated fatty acid, protein.Wherein, in 20 contained several amino acids, comprise that 8 kinds of human bodies must its acid of ammonia.Its most excellent plant unsaturated fatty acid content is 88%, and is rich in folic acid, leaf amide element, 5-hydroxy tryptamine, 106 kinds of bioactive substances such as alkaloid.Through scientific experiments, prove, to nourishing cardiovascular and cerebrovascular vessel, vessel softening, atherosclerosis, thrombosis, cardiac function enhancing, reduction blood fat, adjusting blood pressure, nourishing the liver and kidney have uncommon efficacy effect.
The specific embodiment
Below in conjunction with specific embodiment, technical scheme of the present invention is described further:
Embodiment 1
1, preparation: Folium Ginkgo is cleaned, dried, and pulverizes 80 mesh sieves with pulverizer, and powder is placed in brown wide mouthed bottle and stores; Radix Notoginseng was pulverized 80 mesh sieves and obtained Radix Notoginseng fine powder; Monas cuspurpureus Went is crossed 80 mesh sieves, obtains Monas cuspurpureus Went fine powder;
2, lixiviate is concentrated: 1) take Folium Ginkgo fine powder 500g and Radix Notoginseng fine powder 200g, added in the ethanol that 10 times of amount concentration are 70%, be heated to 65 ℃ in water-bath, lixiviate 1.5h, wherein every 10 minutes, stir once, and filter with husky cloth, obtain extracting solution for the first time; Residual residue adds in the ethanol that 8 times of amount concentration are 70%, and 65 ℃ of water-baths continue lixiviate 1.5h, wherein within every 10 minutes, stirs once, and filtered through gauze, discards medicinal residues, obtains extracting solution for the second time, and extracted twice liquid is merged, standby;
2) get above-mentioned filtrate, put in vacuum decompressioning and concentrating tank, reclaim ethanol to without alcohol taste and to be concentrated into relative density be that 1.20～1.25(50 ℃ of heat is surveyed), obtain thick paste;
3) get above-mentioned thick paste, with reduced vacuum drying baker, be heated to 60 ℃ and be dried, obtain dry extract, and pulverize with universal mill, cross 80 mesh sieves, obtain dry extract;
4) get 200g Herb Gynostemmae Pentaphylli and add 10 times of water, decoct 2 hours, filter to obtain extracting solution for the first time.Residue adds 8 times of water gagings again and decocts 1.5 hours, filters to obtain extracting solution for the second time, concentrated after merge extractive liquid,, adds ethanol to reaching 70% containing alcohol amount, filters, and filtrate is concentrated, is drying to obtain Herb Gynostemmae Pentaphylli extract;
3, colloidal sol: get 250g gelatin, 100ml glycerol and 200ml purified water in the lump in adding glue tank, stir and heat up, after gelatin melts completely, continue to be warming up to 78 ℃, insulated and stirred, being evacuated to viscosity is 2.5-3.5 ten thousand mpas, obtains glue; Described glue is crossed to 80 mesh sieves, move in storage glue tank, 60 ℃ of insulations, standing 6 hours are standby;
4, mix pelleting: by above-mentioned gained Folium Ginkgo, Radix Notoginseng, Herb Gynostemmae Pentaphylli extract and 50g Monas cuspurpureus Went fine powder mix homogeneously and be dissolved in and make fat-reducing soft capsule content in 450ml Fructrs Hippophae seed oil; Use encapsulating machine, with the glue of step 3 preparation and the content of step 4 preparation, be prepared into the soft capsule that specification is 0.6g/ grain, dry, obtain.
The research of test example product auxiliary lipid-lowering function of the present invention human feeding trial
1. test material and method
1.1 are subject to trial product: product compound antihyperglycemic soft capsule of the present invention and placebo sample are provided by Wuhan City mcroorganism Science and Technology Ltd. of unit.Two kinds of basic zero differences of sample packaging, profile and color.Human body recommended amounts every day is 0.6g/ grain * 4 tablet/time * 3 times/day.
1.2 experimenter's mass selections are selected
1.2.1 inclusive criteria: the crowd of simple dyslipidemia, keep usual diet, in half a year, blood sampling is 2 times, as twice serum total cholesterol all >=5.2mmol/L or triglyceride >=1.65mmol/L, all can be used as alternative objects.Non-hyperlipemia of being in hospital meets above-mentioned condition voluntary participation and guarantees cooperation person, all can include test in.The tested phase can keep on ordinary days living and dietary habit.
1.2.2 exclusion standard
1.2.2.1 the age is under-18s or over-65s person.
1.2.2.2 gestation or women breast-feeding their children, to health product allergy sufferers.
1.2.2.3 there are the serious diseases such as severe cardiac, liver, kidney and hemopoietic system, psychotic.
1.2.2.4 take in a short time the article relevant with tested function, have influence on the judgement person to result.
1.2.2.5 do not meet inclusive criteria, do not eat in accordance with regulations given the test agent, cannot judge effect or data not umbra sound effect or safety judgement person.
1.3 EXPERIMENTAL DESIGN and grouping
Between this test employing self and group, contrast two kinds of experimental designs.According to the routine patient of above-mentioned Standard Selection 100, by blood lipid level, be divided at random test group and matched group.Consider that as far as possible the principal element that affects result is as age, sex, diet etc., carry out harmony check, before test-meal test, test group and matched group serum total cholesterol, triglyceride, HDL-C no significant difference (P>0.05).
The dosage of 1.4 given the test agent and using method: test group eats product compound antihyperglycemic soft capsule of the present invention, every day 3 times, each 4, warm boiled water.Matched group is taken placebo.It is 30 days that given the test agent gives the time.Require subject's experimental session not change original dietary habit, normal diet.
1.5 key instruments and reagent
KS21 type blood counting instrument (Japan produce), urinate 11 analysers (Korea S Ying Dong company), OLYMPUS640 automatic clinical chemistry analyzer (Japan's product), and biochemical reagents box is provided by German Lai Bang company.
1.6 observation index
1.6.1 safety indexes
1.6.1.1 general status: the situations such as measuring blood pressure, inquiry spirit, sleep, diet, defecation.
1.6.1.2 blood, urine, just routine examination: whole blood map analysis, urine, just routine examination.
1.6.1.3 liver, kidney function test: total serum protein TP, albumin A LB, glutamic oxaloacetic transaminase, GOT AST, glutamate pyruvate transaminase ALT, total bilirubin TBIL, creatinine CREA, blood urea nitrogen UREA.
1.6.1.4 Abdominal B type ultrasonography, electrocardiogram, x-ray fluoroscopy of chest (Abdominal B type ultrasonography, electrocardiogram, x-ray fluoroscopy of chest check once before test-meal, and each test is once before and after test-meal for all the other indices).
1.6.2 efficiency index
Efficiency index: before and after test group test-meal, serum total cholesterol (TC) reduces > 10%; Triglyceride (TG) reduces > 15%; High density lipoprotein (HDL-C) level rising >0.104mmol/L.
Invalid index: do not reach effective standard person.
2. result
2.1 tested crowd's ordinary circumstances (in Table 1)
The tested crowd's ordinary circumstance of table 1
| Project | Test group | Matched group |
| Number of cases | 50 | 50 |
| Male/female | 38/12 | 39/11 |
| Age (year) | 49.74±10.42 | 47.50±9.71 |
| Body weight (kg) | 73.32±9.97 | 75.37±9.34 |
| Systolic pressure (mmHg) | 129.0±12.94 | 129.2±11.75 |
| Diastolic pressure (mmHg) | 81.20±10.08 | 78.76±13.37 |
| Heart rate/pulse/(beat/min) | 74.64±10.89 | 73.72±11.29 |
| Breathe (beat/min) | 17.38±1.72 | 17.92±1.64 |
2.2 before and after test-meals on the impact of serum total cholesterol and fall serum total cholesterol effective percentage (in Table 2, table 3)
From table 2, take tested material after one month, before and after test group serum total cholesterol self, between comparison and test group and matched group group, comparing difference has significance (P<0.01), and matched group serum total cholesterol changes no significant difference (P>0.05); From table 3, product of the present invention is to reducing serum total cholesterol efficiently individual quantity 46 people, invalid number 4 people, and effective percentage is 92%.
Table 2 product of the present invention is on the impact of serum total cholesterol (mmol/L, x ± s)
Serum total cholesterol effective percentage falls in table 3 product of the present invention
2.3 before and after test-meals on the impact of triglyceride and triglyceride reducing effective percentage (in Table 4, table 5)
From table 4, take tested material after one month, before and after test group self, between comparison and test group and matched group group, comparing difference has significance (P<0.01), and matched group triglyceride changes no significant difference (P>0.05); From table 5, product of the present invention is to reducing serum triglycerides efficiently individual quantity 39 people, invalid number 11 people, and effective percentage is 78%.
Table 4 product of the present invention is on the impact of serum triglycerides (mmol/L, x ± s)
Serum triglycerides effective percentage falls in table 5 product of the present invention
| Group | Number | Effectively | Invalid | Effective percentage (%) |
| Test group | 50 | 39 | 11 | 78 |
| Matched group | 50 | 7 | 43 | 14 |
2.4 before and after test-meals on high density lipoprotein gallbladder with the impact of alcohol and high density lipoprotein increasing cholesterol effective percentage (in Table 6, table 7)
From table 6, take tested material after one month, before and after test group self, between comparison and test-meal group and matched group group, comparing difference has significance (P<0.01), and matched group HDL-C changes no significant difference (P>0.05); From table 7, product of the present invention is to high density lipoprotein increasing cholesterol efficiently individual quantity 31 people, invalid number 19 people, and effective percentage is 62%.
Table 6 product of the present invention is on the impact of HDL-C (mmol/L, x ± s)
Table 7 product high density lipoprotein increasing of the present invention cholesterol effective percentage
| Group | Number | Effectively | Invalid | Effective percentage (%) |
| Test group | 50 | 31 | 19 | 62 |
| Matched group | 50 | 3 | 47 | 6 |
2.5 safety indexs are observed
2.5.1 general status: experimenter took tested material after month, and its blood pressure, diet situation, sleep state, defecation situation and mental status, without significant change, have no obvious adverse reaction.
2.5.2 routine blood test situation of change before and after test-meal.(in Table 9)
Take tested material after one month, test group and matched group routine blood test are all in range of normal value.
Table 9 is taken product of the present invention front and back routine blood test situation of change (x ± s)
2.5.3 liver, renal function situation of change before and after test-meal.(in Table 10)
Take tested material after one month, test group and matched group liver, renal function are all in range of normal value.
Table 10 is taken product of the present invention front and back liver, renal function situation of change (x ± s)
2.5.4 the stool, urine routine inspection result of test-meal before and after test group and matched group is all in range of normal value.
2.5.5 Chest X-rays before test group and matched group test-meal, electrocardiogram, ultrasound diagnosis are normally.
By product auxiliary lipid-lowering function human feeding trial result of study of the present invention, show: take continuously product of the present invention after one month, test group falls that T-CHOL effective percentage is 92.0%, triglyceride reducing effective percentage is 78.0%, HDL-C rising percentage rate is 62.0%.Test group and matched group effective percentage difference have significance (P<0.01).Before and after test group self, between comparison and test group and matched group group, compare, serum total cholesterol, triglyceride, HDL-C difference have significance (P<0.01).
Before and after product test-meal of the present invention, test group and matched group crowd blood, urine, just conventional, the safety indexes such as liver, renal function are all in range of normal value.Duration of test keeps life and dietary habit on ordinary days constant.In test-meal process, do not observe allergy and other untoward reaction, and trencherman is healthy to have no adverse effects to trying.
Should be understood that above-described embodiment is only the preferred embodiment for absolutely proving that the present invention lifts, protection scope of the present invention is not limited to this.Being equal to that those skilled in the art do on basis of the present invention substitutes or conversion, all within protection scope of the present invention.Protection scope of the present invention is as the criterion with claims.
Claims (5)
1. a compound antihyperglycemic soft capsule, is characterized in that, in described compound antihyperglycemic soft capsule, main component is: Folium Ginkgo, Radix Notoginseng, Herb Gynostemmae Pentaphylli, Monas cuspurpureus Went, Fructrs Hippophae seed oil.
2. compound antihyperglycemic soft capsule as claimed in claim 1, it is characterized in that, the weight proportion of described each raw material components Folium Ginkgo, Radix Notoginseng, Herb Gynostemmae Pentaphylli, Monas cuspurpureus Went, Fructrs Hippophae seed oil is: 50 ~ 100 parts of Folium Ginkgos, 20 ~ 30 parts of Radix Notoginseng, 20 ~ 30 parts of Herb Gynostemmae Pentaphylli, 5 ~ 10 parts, Monas cuspurpureus Went, 45 ~ 75 parts of Fructrs Hippophae seed oil.
3. a preparation method for compound antihyperglycemic soft capsule as claimed in claim 1 or 2, is characterized in that, its preparation method comprises the steps:
1) Folium Ginkgo is cleaned, is dried, and pulverizes and sieves;
2) Radix Notoginseng pulverizes and sieves;
3) get ginkgo leaf powder and the Radix Notoginseng powder of weight portion meter, the ethanol that the concentration that adds 10 times of amounts of above-mentioned Chinese medicine powder is 70% is heated to 60 ℃ ~ 70 ℃ in water-bath, lixiviate 1.5h, every 10min stirs once, filters the ethanol that the concentration that adds 8 times of amounts in residue is 70% with husky cloth, 60 ℃ ~ 70 ℃ are continued lixiviate 1.5h, every 10min stirs once, filtered through gauze, and medicinal residues discard, merge extractive liquid,, standby;
4) get above-mentioned filtrate, put in vacuum decompressioning and concentrating tank, reclaim ethanol to without alcohol taste and to be concentrated into relative density be that 1.20 ~ 1.25(50 ℃ of heat is surveyed), obtain thick paste;
5) get above-mentioned thick paste, with reduced vacuum drying baker, be heated to 60 ℃ and be dried, obtain dry extract, and pulverize with universal mill, sieve, obtain dry extract;
6) Herb Gynostemmae Pentaphylli of getting weight portion meter adds 8 ~ 12 times of water, decocts 1.5 ~ 2 hours, and husky cloth filters to obtain extracting solution; Residue adds 5 ~ 8 times of water gagings again and decocts 1 ~ 1.5 hour, filters to obtain extracting solution for the second time, concentrated after merge extractive liquid,, adds ethanol to reaching 70% ~ 90% containing alcohol amount, filters, and filtrate is concentrated, is drying to obtain Herb Gynostemmae Pentaphylli extract;
7) get up-to-standard formula ratio Monas cuspurpureus Went and cross 80 mesh sieves, obtain Monas cuspurpureus Went fine powder;
8) by the gelatin of certain mass umber, glycerol, adding of purified water glue tank, stir and heat up, after gelatin melts completely, continue to be warming up to 75 ℃ ~ 80 ℃, insulated and stirred, being evacuated to viscosity is 2.5-3.5 ten thousand mpas, obtains glue; Described glue is crossed to 60 ~ 80 mesh sieves, move in storage glue tank, 55 ℃ ~ 65 ℃ insulations, standing 4-6 hour is standby;
9) by above-mentioned gained Folium Ginkgo, Radix Notoginseng, Herb Gynostemmae Pentaphylli extract and Monas cuspurpureus Went fine powder mix homogeneously and be dissolved in and make fat-reducing soft capsule content in Fructrs Hippophae seed oil;
10) use encapsulating machine, the capsule 's content of the glue of preparing by step 8) and step 9) preparation is prepared into the soft capsule that specification is 0.6g/ grain, dry, obtains.
4. the preparation method of compound antihyperglycemic soft capsule as claimed in claim 3, is characterized in that, in described step 1), Folium Ginkgo was pulverized 60 ~ 80 mesh sieves; Described step 2) in, Radix Notoginseng was pulverized 60 ~ 80 mesh sieves; Vacuum-concentrcted technological parameter: vacuum 0.08Mpa in described step 4), temperature 60 C; Vacuum drying process parameter in described step 5): baking temperature is 60 ℃, vacuum is 0.08Mpa, dry gained dry extract is crossed 60 ~ 80 mesh sieves.
5. the preparation method of compound antihyperglycemic soft capsule as claimed in claim 3, is characterized in that, in described step 8), glue raw material weight proportioning is 20 ~ 25 parts, gelatin, 8 ~ 10 parts of glycerol, 20 ~ 25 parts of purified water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410047695.9A CN103735603B (en) | 2014-02-11 | 2014-02-11 | A kind of compound antihyperglycemic soft capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410047695.9A CN103735603B (en) | 2014-02-11 | 2014-02-11 | A kind of compound antihyperglycemic soft capsule and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103735603A true CN103735603A (en) | 2014-04-23 |
| CN103735603B CN103735603B (en) | 2016-08-31 |
Family
ID=50492718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410047695.9A Active CN103735603B (en) | 2014-02-11 | 2014-02-11 | A kind of compound antihyperglycemic soft capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103735603B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104585767A (en) * | 2015-02-06 | 2015-05-06 | 北京方中方科技有限公司 | Health product with function of reducing blood fat and preparation process of health product |
| CN106177578A (en) * | 2016-08-26 | 2016-12-07 | 西藏梅邦虫草制品有限公司 | A kind of Chinese medicine composition of blood fat reducing and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1969980A (en) * | 2006-11-06 | 2007-05-30 | 张文武 | Chinese medicinal formulation for treating angina pectoris and preparation process thereof |
| WO2007124674A1 (en) * | 2006-04-20 | 2007-11-08 | Integrated Chinese Medicine Holdings, Ltd. | Compositions for promoting brain and cardiovascular health, preventing and treating brain and cardiovascular disorders |
| CN101612296A (en) * | 2009-06-12 | 2009-12-30 | 贵州百灵企业集团制药股份有限公司 | The purposes of the medicine of treatment cardiac-cerebral vascular diseases, apoplexy sequela in the medicine of preparation treatment fatty liver |
| CN101647942A (en) * | 2009-08-24 | 2010-02-17 | 贵州百灵企业集团制药股份有限公司 | Quality testing method of Yindanxinnaotong soft capsules |
| CN101953918A (en) * | 2010-10-13 | 2011-01-26 | 南方医科大学 | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases |
| CN102552621A (en) * | 2012-02-22 | 2012-07-11 | 成都中医药大学 | Drug combination for treating cardiovascular diseases and preparation method and application of same |
| CN103039977A (en) * | 2012-12-05 | 2013-04-17 | 无锡市天赐康生物科技有限公司 | Healthcare food with functions of immunity improvement and hypoxia tolerance and preparation method thereof |
| CN103083582A (en) * | 2013-02-05 | 2013-05-08 | 孟宪兰 | Medicine for treating hyperlipidemia |
-
2014
- 2014-02-11 CN CN201410047695.9A patent/CN103735603B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007124674A1 (en) * | 2006-04-20 | 2007-11-08 | Integrated Chinese Medicine Holdings, Ltd. | Compositions for promoting brain and cardiovascular health, preventing and treating brain and cardiovascular disorders |
| CN1969980A (en) * | 2006-11-06 | 2007-05-30 | 张文武 | Chinese medicinal formulation for treating angina pectoris and preparation process thereof |
| CN101612296A (en) * | 2009-06-12 | 2009-12-30 | 贵州百灵企业集团制药股份有限公司 | The purposes of the medicine of treatment cardiac-cerebral vascular diseases, apoplexy sequela in the medicine of preparation treatment fatty liver |
| CN101647942A (en) * | 2009-08-24 | 2010-02-17 | 贵州百灵企业集团制药股份有限公司 | Quality testing method of Yindanxinnaotong soft capsules |
| CN101953918A (en) * | 2010-10-13 | 2011-01-26 | 南方医科大学 | Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases |
| CN102552621A (en) * | 2012-02-22 | 2012-07-11 | 成都中医药大学 | Drug combination for treating cardiovascular diseases and preparation method and application of same |
| CN103039977A (en) * | 2012-12-05 | 2013-04-17 | 无锡市天赐康生物科技有限公司 | Healthcare food with functions of immunity improvement and hypoxia tolerance and preparation method thereof |
| CN103083582A (en) * | 2013-02-05 | 2013-05-08 | 孟宪兰 | Medicine for treating hyperlipidemia |
Non-Patent Citations (10)
| Title |
|---|
| 刘红健等: "银丹心脑通治疗脑血栓形成60例临床研究", 《中国中医急症》 * |
| 南京中医药大学: "《中药大辞典》", 31 March 2006, 上海科学技术出版社 * |
| 吕勇辉: "益心健脑胶囊治疗高脂血症疗效观察", 《河南中医学院学报》 * |
| 国家药典委员会: "《中华人民共和国药典》", 31 January 2010, 中国医药科技出版社 * |
| 孙传岐: "降脂通脉丸治疗高脂血症65例", 《山东中医杂志》 * |
| 张兆旺: "《中药药剂学》", 31 January 2003, 中国中医药出版社 * |
| 曹光明: "《中药浸提物生产工艺学》", 30 April 2009, 化学工业出版社 * |
| 田德茂等: "通心调脂胶囊治疗稳定性心绞痛合并高脂血症40例", 《山东中医杂志》 * |
| 高学敏: "《中药学》", 28 February 2003, 中国中医药出版社 * |
| 黎海彬: "降脂中药的研究进展", 《广州城市职业学院学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104585767A (en) * | 2015-02-06 | 2015-05-06 | 北京方中方科技有限公司 | Health product with function of reducing blood fat and preparation process of health product |
| CN106177578A (en) * | 2016-08-26 | 2016-12-07 | 西藏梅邦虫草制品有限公司 | A kind of Chinese medicine composition of blood fat reducing and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103735603B (en) | 2016-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101253903B (en) | Health food with fat-reducing function and its preparation | |
| CN102178314A (en) | Bitter buckwheat health care beverage with auxiliary function for lowering blood pressure and production process thereof | |
| CN106215032A (en) | A kind of bowel relieving weight reducing compound preparation and preparation method thereof | |
| CN102125127B (en) | Functional highland barley red yeast rice tea and preparation method thereof | |
| CN105079089A (en) | Preparation method of kudzuvine root and bitter gourd health-care food assisting in reducing blood glucose | |
| CN107048381A (en) | A kind of health food for improving sleep and preparation method thereof | |
| CN105031517A (en) | Dendrobium officinale healthcare tea capable of reducing blood fat, blood sugar, and blood pressure and preparation method thereof | |
| CN105727145A (en) | Traditional Chinese medicine drug for treating spleen deficiency phlegm-dampness syndrome type hyperlipidaemia | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN106177053A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Pericarpium Citri Reticulatae | |
| CN105999212A (en) | Composition having alcohol effect dispelling effect and preparation method and application thereof | |
| CN106176952A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja and Folium Ilicis | |
| CN103735603B (en) | A kind of compound antihyperglycemic soft capsule and preparation method thereof | |
| CN106173605A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Herba Dendrobii | |
| CN104336596A (en) | Medicine composition capable of lowering blood lipid and preparation method thereof | |
| CN101884671B (en) | Food therapy preparation for preventing and treating asthma based on theories of preventive treatment of disease and medicine food homology | |
| CN106177054A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae | |
| CN106039196B (en) | A pharmaceutical composition for treating hyperlipidemia | |
| CN108498568A (en) | Chinese patent drug, medical food and the preparation method of autoimmune and immune related diseases are treated with Goat Placenta or embryo | |
| CN104857377B (en) | Improve Chinese medical extract of fatty liver and preparation method thereof and massage cream | |
| CN103725587A (en) | Sealwort and hawthorn vinegar and production method thereof | |
| CN104256618B (en) | A kind of hypoglycemic food, health products or pharmaceutical composition | |
| CN103877554B (en) | Pharmaceutical composition for treating heart disease and preparation method and use thereof | |
| CN103181557A (en) | Nutritious food with slimming function and preparation method thereof | |
| CN105995980A (en) | Composition with weight management function and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |